Anthera Pharmaceuticals, Inc.
ANTH
ANTH was delisted on the 27th of June, 2018.
35 hedge funds and large institutions have $3.21M invested in Anthera Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 11 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
13% less funds holding
Funds holding: 40 → 35 (-5)
33% less capital invested
Capital invested by funds: $4.81M → $3.21M (-$1.6M)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$70.1K |
| 2 |
Neuberger Berman Group
New York
|
+$48.3K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
+$45.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$32.3K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$768K |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$82.5K |
| 3 |
ECM
Element Capital Management
New York
|
-$70K |
| 4 |
Goldman Sachs
New York
|
-$69K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$60K |
ANTH Hedge Fund Activity: Q3 2017 in Review
35 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Anthera Pharmaceuticals, Inc. (ANTH) for Q3 2017, worth a combined $3.21M — down 33% from $4.81M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ANTH and 7 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 10 added.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $70.1K. The largest seller was Sabby Management, cutting an estimated $768K.
- 35 institutional investors held Anthera Pharmaceuticals, Inc. (ANTH) as of Q3 2017, down from 40 in Q2 2017.
- Funds reported $3.21M of Anthera Pharmaceuticals, Inc. stock for Q3 2017, down 33% quarter-over-quarter.
- 7 funds opened new Anthera Pharmaceuticals, Inc. positions in Q3 2017 and 11 closed out, a net change of -4 holders.
- The largest Anthera Pharmaceuticals, Inc. buyer in Q3 2017 was Two Sigma Securities, an estimated $70.1K added.
- The largest Anthera Pharmaceuticals, Inc. seller in Q3 2017 was Sabby Management, an estimated $768K sold.
Based on aggregated 13F filings for Q3 2017.